查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1954578

全球胸廓出口症候群 (TOS) 市场：市场规模、占有率、成长率、行业分析、依类型、应用和地区划分的分析以及未来预测 (2026-2034)

Thoracic Outlet Syndrome (TOS) Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 请询问到货日

价格

胸廓出口症候群 (TOS) 市场成长驱动因子

全球胸廓出口症候群 (TOS) 市场正经历稳定成长，其驱动因素包括疾病盛行率的上升、公众意识的增强以及药物治疗优于手术治疗的趋势。预计 2025 年市场规模将达到 2.274 亿美元，2026 年将成长至 2.439 亿美元，到 2034 年将达到 3.6772 亿美元。这意味着在预测期内，复合年增长率 (CAGR) 为 5.27%。北美将在2025年以32.5%的市场占有率引领市场，这得益于其先进的医疗保健基础设施以及胸廓出口综合征在运动员和老年人群中的高发病率。

关于胸廓出口症候群 (TOS)

胸廓出口症候群是由胸廓出口处神经血管结构压迫所引起的疾病。它与创伤、重复性动作和解剖变异有关。症状包括疼痛、麻木和肿胀，根据亚型（例如神经源性胸廓出口症候群 (nTOS)、静脉性胸廓出口症候群和动脉性胸廓出口症候群），它可能影响神经、静脉或动脉。

市场驱动因素

市场成长的主要驱动因素是扩大采用药物治疗而非手术减压。医师倾向于使用药物来缓解症状，延缓或避免手术，尤其是在神经源性胸廓出口症候群（nTOS）的治疗中。例如，马斯垂克大学2022年的一项研究证实了保守治疗对nTOS患者的有效性，进一步巩固了药物作为第一线治疗方案的地位。此外，诸如Sunshine BioPharma公司生产的加巴喷丁（预计于2025年6月上市）等非适应症用仿製药的上市，正在进一步拓展治疗选择和市场覆盖范围。 市场限制与挑战 主要限制因素是缺乏FDA或EMA核准的专门用于治疗TOS的药物。所有可用的药物均属于非适应症用药，这可能会削弱医生的信心并限制市场扩张。此外，缺乏标准化的诊断标准导致误诊率高，治疗启动延迟。哥德堡大学2023年的一项研究强调了这项挑战，发现超过30%的nTOS病例最初被误诊。 机遇 标靶神经调节剂和抗惊厥药物的研发为市场成长带来了广阔的机会。这些疗法旨在精准放鬆高张力肌肉，比传统非类固醇抗发炎药物 (NSAIDs) 或肌肉鬆弛剂更有效地缓解神经痛。例如，2024 年发表在 "肌肉与神经杂誌" (Muscle & Nerve Journal) 上的一项随机对照试验报告称，肉毒桿菌注射对神经源性胸廓出口综合征 (nTOS) 患者有益，这表明这种创新疗法具有巨大的潜力。 市场区隔

  • 依药物类别划分：非类固醇抗发炎药物 (NSAIDs) 广泛用于治疗神经源性胸廓出口症候群 (nTOS) 引起的疼痛和炎症，占所有胸廓出口症候群病例的 90%，因此占市场主导地位。其他药物类别包括抗凝血剂、血栓溶解剂、肌肉鬆弛剂和皮质类固醇。
  • 依类型划分：神经源性胸廓出口症候群（TOS）占最大市场占有率，预计2025年患病率将高达87.6%。静脉型和动脉型TOS的市占率较小，但预计将保持稳定成长，其中静脉型胸廓出口症候群在预测期内的复合年增长率（CAGR）预计为4.67%。
  • 依给药途径划分：口服给药是主要给药途径，由于其便利性和可近性，预计2024年将占66.3%的市占率。肠外给药和其他给药途径预计将以适度的速度成长，复合年增长率约为4.54%。
  • 依分销管道划分：零售药局和药局是主要分销管道，预计2025年将占53.2%的市场占有率，这得益于非类固醇抗发炎药（NSAIDs）和其他非适应症用药的可及性和广泛分销。医院药房和网路药房正在稳步增长。

区域洞察

北美引领全球TOS市场，预计美国市场规模将在2025年达到6,670万美元。欧洲紧随其后，疾病盛行率的上升和宣传活动的发展推动了市场规模在2025年达到5,910万美元。其中，德国为1,220万美元，法国为940万美元，英国为1,040万美元。亚太地区将成为第三大市场，预计在2025年达到6,820万美元，其中印度和中国分别贡献1,090万美元和1,670万美元。拉丁美洲和中东及非洲地区预计将实现温和成长，市场规模预计在2025年分别达到1,390万美元和590万美元。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：主要发现

  • 胸廓出口症候群盛行率：依主要国家/地区划分（2025 年）
  • 主要产业趋势（新产品发表、併购、合作等）
  • 主要公司产品线分析
  • 主要国家的监管和报销情况

章节5 全球胸廓出口症候群 (TOS) 市场分析：洞察与预测 (2021-2034)

  • 市场分析、洞察与预测：依药物类别划分
    • 抗凝血剂
    • 溶栓剂
    • 非类固醇类抗发炎药 (NSAIDs)
    • 肌肉鬆弛剂
    • 皮质类固醇
    • 其他
  • 市场分析、洞察与预测：依类型划分
    • 神经性 TOS（胸廓出口症候群）
    • 静脉性 TOS（胸廓出口症候群）
    • 动脉性 TOS（胸廓出口症候群）（口腔型）
  • 市场分析、洞察与预测：依给药途径划分给药途径
    • 口服
    • 肠外给药
    • 其他
  • 市场分析、洞察与预测：依销售管道划分
    • 医院药房
    • 零售药局和药局
    • 线上药房
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章 北美胸廓出口症候群 (TOS) 市场分析：洞察与预测 (2021-2034)

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲胸廓出口症候群市场分析胸廓出口症候群 (TOS) 市场：洞察与预测 (2021-2034)

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 其他欧洲国家

第八章 亚太地区胸廓出口症候群 (TOS) 市场规模（估算与预测）：依细分市场划分 (2021-2034)

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 东南亚
    • 其他亚太地区

第九章 拉丁美洲胸廓出口症候群 (TOS) 市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 其他拉丁美洲国家

第十章 中东与非洲胸廓出口症候群 (TOS) 市场分析：洞察与预测（2021-2034）

  • 国家细分
    • 海湾合作委员会 (GCC)
    • 南非
    • 其他中东和非洲国家

第11章 竞争分析

  • 世界市场占有率分析(2025年)
  • 企业简介
  • Bayer AG
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Sun Pharmaceutical Industries Ltd.
  • Assertio Therapeutics, Inc.
  • Daiichi Sankyo Co., Ltd.
  • Takeda Pharmaceutical Company Limited
Product Code: FBI114374

Growth Factors of thoracic outlet syndrome (TOS) Market

The global thoracic outlet syndrome (TOS) market is witnessing steady growth, driven by rising disease prevalence, increasing awareness, and the preference for pharmacologic management over surgical intervention. The market was valued at USD 227.4 million in 2025 and is projected to grow to USD 243.9 million in 2026, reaching USD 367.72 million by 2034, reflecting a CAGR of 5.27% over the forecast period. North America dominated the market in 2025 with a 32.5% share, supported by advanced healthcare infrastructure and a high prevalence of TOS among athletes and elderly populations.

Understanding Thoracic Outlet Syndrome (TOS)

Thoracic outlet syndrome is a condition resulting from compression of neurovascular structures in the thoracic outlet. It is linked to trauma, repetitive activity, and anatomical variations. Symptoms may include pain, numbness, and swelling, and can affect the nerves, veins, or arteries depending on the subtype: neurogenic TOS (nTOS), venous TOS, or arterial TOS.

Market Drivers

A key driver of market growth is the increasing adoption of pharmacologic management before surgical decompression. Physicians prefer medications to relieve symptoms and delay or avoid surgery, especially for neurogenic TOS. For instance, a 2022 Maastricht University study demonstrated the effectiveness of conservative therapy in patients with nTOS, reinforcing the role of drugs as first-line treatment. Additionally, product launches of off-label generic drugs, such as Sunshine Biopharma Inc.'s Gabapentin in June 2025, further expand treatment options and market reach.

Market Restraints and Challenges

A major restraint is the absence of FDA or EMA-approved drugs specifically for TOS. All available medications are off-label, which may limit physician confidence and restrict market expansion. Furthermore, the lack of standardized diagnostic criteria leads to frequent misdiagnosis, delaying treatment initiation. A 2023 study by the University of Gothenburg found that over 30% of nTOS cases were initially misdiagnosed, highlighting this challenge.

Opportunities

The development of targeted neuro-modulatory and anti-spasm agents represents a promising opportunity for market growth. These therapies aim to precisely relax hypertonic muscles and alleviate nerve pain more effectively than conventional NSAIDs or muscle relaxants. For example, a 2024 randomized controlled trial published in Muscle & Nerve Journal reported beneficial outcomes using Botox injections in nTOS patients, indicating potential for innovative therapeutics.

Market Segmentation

  • By Drug Class: NSAIDs dominate the market due to their widespread use for pain and inflammation in neurogenic TOS, which accounts for 90% of total cases. Other drug classes include anticoagulants, thrombolytics, muscle relaxants, corticosteroids, and others.
  • By Type: Neurogenic TOS holds the largest share, with 87.6% in 2025, reflecting its high prevalence. Venous TOS and arterial TOS represent smaller market shares but are projected to grow steadily, with venous TOS showing a CAGR of 4.67% over the forecast period.
  • By Route of Administration: Oral medications dominate with 66.3% share in 2024, due to convenience and availability. Parenteral and other routes are expected to grow at a moderate pace of around 4.54% CAGR.
  • By Distribution Channel: Retail pharmacies and drug stores are the leading distribution channels, projected to account for 53.2% in 2025, driven by easy accessibility and widespread availability of NSAIDs and other off-label drugs. Hospital pharmacies and online pharmacies are growing steadily.

Regional Insights

North America leads the global TOS market, with the U.S. market projected at USD 66.7 million in 2025. Europe follows, expected to reach USD 59.1 million in 2025, driven by rising disease prevalence and awareness campaigns, with Germany at USD 12.2 million, France USD 9.4 million, and the U.K. USD 10.4 million. Asia Pacific is the third-largest region, projected at USD 68.2 million in 2025, with India and China contributing USD 10.9 million and USD 16.7 million, respectively. Latin America and the Middle East & Africa are forecasted to show moderate growth, with valuations of USD 13.9 million and USD 5.9 million respectively in 2025.

Competitive Landscape

The TOS market is fragmented with major players including Bayer AG (Germany), Pfizer Inc. (U.S.), Bristol-Myers Squibb (U.S.), Sun Pharmaceutical Industries (India), Assertio Therapeutics (U.S.), Daiichi Sankyo (Japan), and Takeda Pharmaceutical (U.S.). These companies focus on expanding their product portfolios with branded and generic drugs and strengthening research and development initiatives. Key developments include Lupin's generic rivaroxaban launch in October 2025 and Sandoz's introduction of new rivaroxaban strengths in Germany in August 2025.

Conclusion

The global TOS market is poised for steady growth from 2025 to 2034. Rising disease prevalence, increased awareness programs, and the shift toward pharmacologic management before surgery are key drivers. While lack of approved drugs and standardized diagnostics pose challenges, innovations in targeted therapies and the expansion of off-label medications are expected to sustain market growth. North America continues to lead, followed by Europe and Asia Pacific, with opportunities for expansion in emerging regions through enhanced awareness and improved access to therapeutics.

Segmentation By Drug Class, Type, Route of Administration, Distribution Channel, and Region

By Drug Class * Anticoagulants

  • Thrombolytics
  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • Muscle Relaxants
  • Corticosteroids
  • Others

By Type * Neurogenic TOS

  • Venous TOS
  • Arterial TOS

By Route of Administration * Oral

  • Parenteral
  • Others

By Distribution Channel * Hospital Pharmacies

  • Retail Pharmacies & Drug Stores
  • Online Pharmacies

By Region * North America (By Drug Class, Type, Route of Administration, Distribution Channel, and Country)

    • U.S.
    • Canada
  • Europe (By Drug Class, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Class, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Thoracic Outlet Syndrome, By Key Countries, 2025
  • 4.2. Key Industry Developments (Launches, Mergers, Acquisitions, Partnerships, etc.)
  • 4.3. Pipeline Analysis, By Key Players
  • 4.4. Regulatory & Reimbursement Scenario, By Key Countries

5. Global Thoracic Outlet Syndrome (TOS) Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Anticoagulants
    • 5.1.2. Thrombolytics
    • 5.1.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 5.1.4. Muscle Relaxants
    • 5.1.5. Corticosteroids
    • 5.1.6. Others
  • 5.2. Market Analysis, Insights and Forecast - By Type
    • 5.2.1. Neurogenic TOS
    • 5.2.2. Venous TOS
    • 5.2.3. Arterial TOS
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Retail Pharmacies & Drug Stores
    • 5.4.3. Online Pharmacies
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Thoracic Outlet Syndrome (TOS) Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Anticoagulants
    • 6.1.2. Thrombolytics
    • 6.1.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 6.1.4. Muscle Relaxants
    • 6.1.5. Corticosteroids
    • 6.1.6. Others
  • 6.2. Market Analysis, Insights and Forecast - By Type
    • 6.2.1. Neurogenic TOS
    • 6.2.2. Venous TOS
    • 6.2.3. Arterial TOS
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Retail Pharmacies & Drug Stores
    • 6.4.3. Online Pharmacies
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Thoracic Outlet Syndrome (TOS) Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Anticoagulants
    • 7.1.2. Thrombolytics
    • 7.1.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 7.1.4. Muscle Relaxants
    • 7.1.5. Corticosteroids
    • 7.1.6. Others
  • 7.2. Market Analysis, Insights and Forecast - By Type
    • 7.2.1. Neurogenic TOS
    • 7.2.2. Venous TOS
    • 7.2.3. Arterial TOS
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Retail Pharmacies & Drug Stores
    • 7.4.3. Online Pharmacies
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Thoracic Outlet Syndrome (TOS) Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Anticoagulants
    • 8.1.2. Thrombolytics
    • 8.1.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 8.1.4. Muscle Relaxants
    • 8.1.5. Corticosteroids
    • 8.1.6. Others
  • 8.2. Market Analysis, Insights and Forecast - By Type
    • 8.2.1. Neurogenic TOS
    • 8.2.2. Venous TOS
    • 8.2.3. Arterial TOS
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Retail Pharmacies & Drug Stores
    • 8.4.3. Online Pharmacies
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Thoracic Outlet Syndrome (TOS) Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Anticoagulants
    • 9.1.2. Thrombolytics
    • 9.1.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 9.1.4. Muscle Relaxants
    • 9.1.5. Corticosteroids
    • 9.1.6. Others
  • 9.2. Market Analysis, Insights and Forecast - By Type
    • 9.2.1. Neurogenic TOS
    • 9.2.2. Venous TOS
    • 9.2.3. Arterial TOS
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Retail Pharmacies & Drug Stores
    • 9.4.3. Online Pharmacies
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Thoracic Outlet Syndrome (TOS) Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Anticoagulants
    • 10.1.2. Thrombolytics
    • 10.1.3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • 10.1.4. Muscle Relaxants
    • 10.1.5. Corticosteroids
    • 10.1.6. Others
  • 10.2. Market Analysis, Insights and Forecast - By Type
    • 10.2.1. Neurogenic TOS
    • 10.2.2. Venous TOS
    • 10.2.3. Arterial TOS
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Parenteral
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Retail Pharmacies & Drug Stores
    • 10.4.3. Online Pharmacies
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 11.2.1. Bayer AG
    • 11.2.2. Pfizer Inc.
    • 11.2.3. Bristol-Myers Squibb Company
    • 11.2.4. Sun Pharmaceutical Industries Ltd.
    • 11.2.5. Assertio Therapeutics, Inc.
    • 11.2.6. Daiichi Sankyo Co., Ltd.
    • 11.2.7. Takeda Pharmaceutical Company Limited

List of Tables

  • Table 1: Global Thoracic Outlet Syndrome (TOS) Market Revenue (USD million) Forecast, by Drug Class, 2021-2034
  • Table 2: Global Thoracic Outlet Syndrome (TOS) Market Revenue (USD million) Forecast, by Type, 2021-2034
  • Table 3: Global Thoracic Outlet Syndrome (TOS) Market Revenue (USD million) Forecast, by Route of Administration, 2021-2034
  • Table 4: Global Thoracic Outlet Syndrome (TOS) Market Revenue (USD million) Forecast, by Distribution Channel, 2021-2034
  • Table 5: Global Thoracic Outlet Syndrome (TOS) Market Revenue (USD million) Forecast, by Region, 2021-2034
  • Table 6: North America Thoracic Outlet Syndrome (TOS) Market Revenue (USD million) Forecast, by Drug Class, 2021-2034
  • Table 7: North America Thoracic Outlet Syndrome (TOS) Market Revenue (USD million) Forecast, by Type, 2021-2034
  • Table 8: North America Thoracic Outlet Syndrome (TOS) Market Revenue (USD million) Forecast, by Route of Administration, 2021-2034
  • Table 9: North America Thoracic Outlet Syndrome (TOS) Market Revenue (USD million) Forecast, by Distribution Channel, 2021-2034
  • Table 10: North America Thoracic Outlet Syndrome (TOS) Market Revenue (USD million) Forecast, By Country, 2021-2034
  • Table 11: Europe Thoracic Outlet Syndrome (TOS) Market Revenue (USD million) Forecast, by Drug Class, 2021-2034
  • Table 12: Europe Thoracic Outlet Syndrome (TOS) Market Revenue (USD million) Forecast, by Type, 2021-2034
  • Table 13: Europe Thoracic Outlet Syndrome (TOS) Market Revenue (USD million) Forecast, by Route of Administration, 2021-2034
  • Table 14: Europe Thoracic Outlet Syndrome (TOS) Market Revenue (USD million) Forecast, by Distribution Channel, 2021-2034
  • Table 15: Europe Thoracic Outlet Syndrome (TOS) Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Thoracic Outlet Syndrome (TOS) Market Revenue (USD million) Forecast, by Drug Class, 2021-2034
  • Table 17: Asia Pacific Thoracic Outlet Syndrome (TOS) Market Revenue (USD million) Forecast, by Type, 2021-2034
  • Table 18: Asia Pacific Thoracic Outlet Syndrome (TOS) Market Revenue (USD million) Forecast, by Route of Administration, 2021-2034
  • Table 19: Asia Pacific Thoracic Outlet Syndrome (TOS) Market Revenue (USD million) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Asia Pacific Thoracic Outlet Syndrome (TOS) Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Latin America Thoracic Outlet Syndrome (TOS) Market Revenue (USD million) Forecast, by Drug Class, 2021-2034
  • Table 22: Latin America Thoracic Outlet Syndrome (TOS) Market Revenue (USD million) Forecast, by Type, 2021-2034
  • Table 23: Latin America Thoracic Outlet Syndrome (TOS) Market Revenue (USD million) Forecast, by Route of Administration, 2021-2034
  • Table 24: Latin America Thoracic Outlet Syndrome (TOS) Market Revenue (USD million) Forecast, by Distribution Channel, 2021-2034
  • Table 25: Latin America Thoracic Outlet Syndrome (TOS) Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Thoracic Outlet Syndrome (TOS) Market Revenue (USD million) Forecast, by Drug Class, 2021-2034
  • Table 27: Middle East & Africa Thoracic Outlet Syndrome (TOS) Market Revenue (USD million) Forecast, by Type, 2021-2034
  • Table 28: Middle East & Africa Thoracic Outlet Syndrome (TOS) Market Revenue (USD million) Forecast, by Route of Administration, 2021-2034
  • Table 29: Middle East & Africa Thoracic Outlet Syndrome (TOS) Market Revenue (USD million) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Middle East & Africa Thoracic Outlet Syndrome (TOS) Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Thoracic Outlet Syndrome (TOS) Market Revenue Breakdown (USD million, %) by Region, 2025 & 2034
  • Figure 2: Global Thoracic Outlet Syndrome (TOS) Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Thoracic Outlet Syndrome (TOS) Market Value Share (%), by Type, 2025 & 2034
  • Figure 4: Global Thoracic Outlet Syndrome (TOS) Market Value Share (%), by Route of Administration 2025 & 2034
  • Figure 5: Global Thoracic Outlet Syndrome (TOS) Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 6: Global Thoracic Outlet Syndrome (TOS) Market Value Share (%), by Region, 2025 & 2034
  • Figure 7: North America Thoracic Outlet Syndrome (TOS) Market Value (USD million), by Drug Class, 2025 & 2034
  • Figure 8: North America Thoracic Outlet Syndrome (TOS) Market Value Share (%), by Drug Class, 2025
  • Figure 9: North America Thoracic Outlet Syndrome (TOS) Market Value (USD million), by Type, 2025 & 2034
  • Figure 10: North America Thoracic Outlet Syndrome (TOS) Market Value Share (%), by Type, 2025
  • Figure 11: North America Thoracic Outlet Syndrome (TOS) Market Value (USD million), by Route of Administration, 2025 & 2034
  • Figure 12: North America Thoracic Outlet Syndrome (TOS) Market Value Share (%), by Route of Administration, 2025
  • Figure 13: North America Thoracic Outlet Syndrome (TOS) Market Value (USD million), by Distribution Channel, 2025 & 2034
  • Figure 14: North America Thoracic Outlet Syndrome (TOS) Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: North America Thoracic Outlet Syndrome (TOS) Market Value (USD million), By Country, 2025 & 2034
  • Figure 16: North America Thoracic Outlet Syndrome (TOS) Market Value Share (%), By Country, 2025
  • Figure 17: Europe Thoracic Outlet Syndrome (TOS) Market Value (USD million), by Drug Class, 2025 & 2034
  • Figure 18: Europe Thoracic Outlet Syndrome (TOS) Market Value Share (%), by Drug Class, 2025
  • Figure 19: Europe Thoracic Outlet Syndrome (TOS) Market Value (USD million), by Type, 2025 & 2034
  • Figure 20: Europe Thoracic Outlet Syndrome (TOS) Market Value Share (%), by Type, 2025
  • Figure 21: Europe Thoracic Outlet Syndrome (TOS) Market Value (USD million), by Route of Administration, 2025 & 2034
  • Figure 22: Europe Thoracic Outlet Syndrome (TOS) Market Value Share (%), by Route of Administration, 2025
  • Figure 23: Europe Thoracic Outlet Syndrome (TOS) Market Value (USD million), by Distribution Channel, 2025 & 2034
  • Figure 24: Europe Thoracic Outlet Syndrome (TOS) Market Value Share (%), by Distribution Channel, 2025
  • Figure 25: Europe Thoracic Outlet Syndrome (TOS) Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Thoracic Outlet Syndrome (TOS) Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Thoracic Outlet Syndrome (TOS) Market Value (USD million), by Drug Class, 2025 & 2034
  • Figure 28: Asia Pacific Thoracic Outlet Syndrome (TOS) Market Value Share (%), by Drug Class, 2025
  • Figure 29: Asia Pacific Thoracic Outlet Syndrome (TOS) Market Value (USD million), by Type, 2025 & 2034
  • Figure 30: Asia Pacific Thoracic Outlet Syndrome (TOS) Market Value Share (%), by Type, 2025
  • Figure 31: Asia Pacific Thoracic Outlet Syndrome (TOS) Market Value (USD million), by Route of Administration, 2025 & 2034
  • Figure 32: Asia Pacific Thoracic Outlet Syndrome (TOS) Market Value Share (%), by Route of Administration, 2025
  • Figure 33: Asia Pacific Thoracic Outlet Syndrome (TOS) Market Value (USD million), by Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Thoracic Outlet Syndrome (TOS) Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Asia Pacific Thoracic Outlet Syndrome (TOS) Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Thoracic Outlet Syndrome (TOS) Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Thoracic Outlet Syndrome (TOS) Market Value (USD million), by Drug Class, 2025 & 2034
  • Figure 38: Latin America Thoracic Outlet Syndrome (TOS) Market Value Share (%), by Drug Class, 2025
  • Figure 39: Latin America Thoracic Outlet Syndrome (TOS) Market Value (USD million), by Type, 2025 & 2034
  • Figure 40: Latin America Thoracic Outlet Syndrome (TOS) Market Value Share (%), by Type, 2025
  • Figure 41: Latin America Thoracic Outlet Syndrome (TOS) Market Value (USD million), by Route of Administration, 2025 & 2034
  • Figure 42: Latin America Thoracic Outlet Syndrome (TOS) Market Value Share (%), by Route of Administration, 2025
  • Figure 43: Latin America Thoracic Outlet Syndrome (TOS) Market Value (USD million), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Thoracic Outlet Syndrome (TOS) Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Thoracic Outlet Syndrome (TOS) Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Thoracic Outlet Syndrome (TOS) Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Thoracic Outlet Syndrome (TOS) Market Value (USD million), by Drug Class, 2025 & 2034
  • Figure 48: Middle East & Africa Thoracic Outlet Syndrome (TOS) Market Value Share (%), by Drug Class, 2025
  • Figure 49: Middle East & Africa Thoracic Outlet Syndrome (TOS) Market Value (USD million), by Type, 2025 & 2034
  • Figure 50: Middle East & Africa Thoracic Outlet Syndrome (TOS) Market Value Share (%), by Type, 2025
  • Figure 51: Middle East & Africa Thoracic Outlet Syndrome (TOS) Market Value (USD million), by Route of Administration, 2025 & 2034
  • Figure 52: Middle East & Africa Thoracic Outlet Syndrome (TOS) Market Value Share (%), by Route of Administration, 2025
  • Figure 53: Middle East & Africa Thoracic Outlet Syndrome (TOS) Market Value (USD million), by Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Thoracic Outlet Syndrome (TOS) Market Value Share (%), by Distribution Channel, 2025
  • Figure 55: Middle East & Africa Thoracic Outlet Syndrome (TOS) Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Thoracic Outlet Syndrome (TOS) Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 57: Global Thoracic Outlet Syndrome (TOS) Market Share (%), By Company, 2025